Halozyme Therapeutics just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Halozyme Therapeutics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Halozyme Therapeutics Offers to Acquire Germany-Based Evotec for ~$2 Billion
Contract Type
partnership
San DiegoManufacturingBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
Halozyme Therapeutics announced its non-binding proposal to acquire Evotec SE for 2.0 billion euros, representing a premium of 109% to Evotec’s undisturbed share price. The proposed partnership aims to diversify and extend Halozyme's revenue and EBITDA growth, enable ongoing investments in Evotec’s early-stage programs and new technologies, and significantly expand and diversify Halozyme’s revenue and EBITDA over the next decade.